Isaac Carrasco
Research Subjects
Isaac Carrasco has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anna Puigdemont
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain
4 shared publications Ana Prats
Clínica Felina Barcelona Carrer Marquès del Campo Sagrado, 12 Barcelona 08015 Spain
1 shared publicationAnna Calvet
Clínica Felina Barcelona Carrer Marquès del Campo Sagrado, 12 Barcelona 08015 Spain
1 shared publication- Antonio Meléndez‐Lazo
T‐Cito Barcelona Spain
1 shared publication Carles Cristòfol
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193, Bellaterra, Barcelona, Spain
1 shared publication- Dolors Fondevila
Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Barcelona, Spain
1 shared publication
Latest Publications
- 8 August 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (4) , 558-566
Comparative Evaluation of Cytological and Histopathological Diagnostic Performance in Detecting Nodal Metastasis of Canine Mast Cell Tumours
Cytological evaluation of regional lymph nodes (LNs) is routinely used for staging canine mast cell tumours (MCTs), but its diagnostic accuracy requires further validation. This multicentre retrospective study compared Krick's cytological criteria with Weishaar's histopathological classification for detecting LN metastasis in canine MCTs, and evaluated whether cytology with modified Wright‐Giemsa stain (WGS) could outperform routine haematoxylin–eosin (H&E) histology in identifying early metastatic LNs. Paired cytological and histopathological evaluations were performed on 65 LNs from 52 dogs undergoing lymphadenectomy, with toluidine blue staining (TBS) applied when metastasis was not evident on H&E. Cytology samples were classified using Krick's criteria (normal/reactive, possible, probable, certain metastasis). Histopathology was graded according to Weishaar's system (HN0–HN3). Diagnostic performance was assessed for three cytologic positivity groups (G): G1 (certain), G2 (certain/probable), and G3 (certain/probable/possible). Cytology detected 87.5% of early (HN2) and 95% of overt (HN3) metastases, outperforming H&E (25% and 85%, respectively). G1 showed moderate sensitivity (75%) but high specificity (93.1%), positive predictive value (93.1%), and positive likelihood ratio (10.5). G3 yielded the highest sensitivity (91.7%) but the lowest specificity (62.1%), with a negative predictive value of 85.7% and a negative likelihood ratio of 0.13. ROC analysis revealed notable diagnostic performance with Kappa values indicating moderate to substantial agreement between cytology and histopathology. Our results validate cytology with WGS as a reliable tool for LN staging in MCTs, outperforming routine H&E histology in the detection of early metastatic LNs. However, the ‘possible’ and ‘probable’ categories should be interpreted cautiously. TBS is essential for accurate nodal histopathological assessment. Definitive staging should integrate histopathology and advanced nodal mapping techniques to optimise sentinel LN identification.
- 8 August 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (4) , 558-566
Comparative Evaluation of Cytological and Histopathological Diagnostic Performance in Detecting Nodal Metastasis of Canine Mast Cell Tumours
Cytological evaluation of regional lymph nodes (LNs) is routinely used for staging canine mast cell tumours (MCTs), but its diagnostic accuracy requires further validation. This multicentre retrospective study compared Krick's cytological criteria with Weishaar's histopathological classification for detecting LN metastasis in canine MCTs, and evaluated whether cytology with modified Wright‐Giemsa stain (WGS) could outperform routine haematoxylin–eosin (H&E) histology in identifying early metastatic LNs. Paired cytological and histopathological evaluations were performed on 65 LNs from 52 dogs undergoing lymphadenectomy, with toluidine blue staining (TBS) applied when metastasis was not evident on H&E. Cytology samples were classified using Krick's criteria (normal/reactive, possible, probable, certain metastasis). Histopathology was graded according to Weishaar's system (HN0–HN3). Diagnostic performance was assessed for three cytologic positivity groups (G): G1 (certain), G2 (certain/probable), and G3 (certain/probable/possible). Cytology detected 87.5% of early (HN2) and 95% of overt (HN3) metastases, outperforming H&E (25% and 85%, respectively). G1 showed moderate sensitivity (75%) but high specificity (93.1%), positive predictive value (93.1%), and positive likelihood ratio (10.5). G3 yielded the highest sensitivity (91.7%) but the lowest specificity (62.1%), with a negative predictive value of 85.7% and a negative likelihood ratio of 0.13. ROC analysis revealed notable diagnostic performance with Kappa values indicating moderate to substantial agreement between cytology and histopathology. Our results validate cytology with WGS as a reliable tool for LN staging in MCTs, outperforming routine H&E histology in the detection of early metastatic LNs. However, the ‘possible’ and ‘probable’ categories should be interpreted cautiously. TBS is essential for accurate nodal histopathological assessment. Definitive staging should integrate histopathology and advanced nodal mapping techniques to optimise sentinel LN identification.
- Open Access
- 23 December 2024
- Published by Aditum Publishing LLC in Journal of Veterinary Medicine and Science
- Vol. 1 (2) , 1-5
Subcutaneous Panniculitis-Like T-Cell Lymphoma in Two Dogs with Indolent Progression, As A Clinical and Histopathological Form of Non-Epitheliotropic Lymphoma
The subcutaneous panniculitis-like form of non-epitheliotropic T-cell lymphoma (SPTCL) has previously been described in dogs and is generally associated with poor prognosis. We describe two cases that showed a slow and benign progression, similar to the a-b T-cell phenotype without haemophagocytic syndrome form of the disease observed in humans. In contrast to the more aggressive g-d phenotype, the T-cells involved in this form of SPTCL in humans are CD30- and CD56-, as seen in the present cases, highlighting their potential as prognostic markers for a better outcome also in dogs.
- 23 December 2024
- Published by Aditum Publishing LLC in Journal of Veterinary Medicine and Science
- Vol. 1 (2) , 1-5
Open AccessSubcutaneous Panniculitis-Like T-Cell Lymphoma in Two Dogs with Indolent Progression, As A Clinical and Histopathological Form of Non-Epitheliotropic Lymphoma
The subcutaneous panniculitis-like form of non-epitheliotropic T-cell lymphoma (SPTCL) has previously been described in dogs and is generally associated with poor prognosis. We describe two cases that showed a slow and benign progression, similar to the a-b T-cell phenotype without haemophagocytic syndrome form of the disease observed in humans. In contrast to the more aggressive g-d phenotype, the T-cells involved in this form of SPTCL in humans are CD30- and CD56-, as seen in the present cases, highlighting their potential as prognostic markers for a better outcome also in dogs.
- 6 October 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (8) , 787-793
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response
Objectives: The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects. Methods: Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12h for 2 weeks and then at 1 mg/kg q24h for a further 2 weeks. At the study outset (D0), and 7 (D7) and 28 (D28) days after starting treatment, clinical lesions were assessed using a validated scoring system (SCORing Feline Allergic Dermatitis [SCORFAD]) and pruritus was graded via an adapted visual analogue scale (PVAS). At the same time points, plasma oclacitinib levels and haematological variables were measured. Results: Among 18 cats completing the study, PVAS and SCORFAD improved by ⩾50% in 61% and 88% of animals, respectively. Mean PVAS decreased significantly between D0 and D7 and between D0 and D28 (both P P <0.001) but not between D7 and D28. On D7 and D28, plasma oclacitinib concentrations varied widely from 0 to 1443.2 ng/ml and from from 0 to 1177.7 ng/ml, respectively. Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). Conclusions and relevance: Oclacitinib emerged as being safe and effective to control clinical signs of FASS. A mean dose of 1 mg/kg, even without extending twice-daily treatment beyond the first 2 weeks, could be a suitable therapeutic regimen. Plasma drug levels did not seem useful to predict clinical response during treatment.
- 6 October 2021
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 24 (8) , 787-793
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response
Objectives: The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects. Methods: Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12h for 2 weeks and then at 1 mg/kg q24h for a further 2 weeks. At the study outset (D0), and 7 (D7) and 28 (D28) days after starting treatment, clinical lesions were assessed using a validated scoring system (SCORing Feline Allergic Dermatitis [SCORFAD]) and pruritus was graded via an adapted visual analogue scale (PVAS). At the same time points, plasma oclacitinib levels and haematological variables were measured. Results: Among 18 cats completing the study, PVAS and SCORFAD improved by ⩾50% in 61% and 88% of animals, respectively. Mean PVAS decreased significantly between D0 and D7 and between D0 and D28 (both P P <0.001) but not between D7 and D28. On D7 and D28, plasma oclacitinib concentrations varied widely from 0 to 1443.2 ng/ml and from from 0 to 1177.7 ng/ml, respectively. Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). Conclusions and relevance: Oclacitinib emerged as being safe and effective to control clinical signs of FASS. A mean dose of 1 mg/kg, even without extending twice-daily treatment beyond the first 2 weeks, could be a suitable therapeutic regimen. Plasma drug levels did not seem useful to predict clinical response during treatment.
- 15 March 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (3) , 299-301
Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus
Pemphigus foliaceous (PF) is a pustular, immune‐mediated skin disease characterised by acantholytic cells and commonly treated with high doses of glucocorticoids. This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases.
- 15 March 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (3) , 299-301
Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus
Pemphigus foliaceous (PF) is a pustular, immune‐mediated skin disease characterised by acantholytic cells and commonly treated with high doses of glucocorticoids. This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases.
- 5 January 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (1) , 67-e12
Clinical efficacy of sublingual allergen‐specific immunotherapy in 22 cats with atopic dermatitis
Background: Sublingual immunotherapy (SLIT) has been deployed in humans and dogs; to the best of the authors’ knowledge, there are no published studies about the use of SLIT in cats.Objectives: Evaluate the clinical efficacy of SLIT in atopic cats sensitized to dust and storage mites, assessing immunological changes associated with SLIT treatment.Animals: Twenty‐two client‐owned cats with clinical signs compatible with feline atopic dermatitis (fAD) and serum allergen‐specific immunoglobulin (Ig)E against house dust and storage mites.Methods and materials: Prospective, multicentre, open‐label clinical trial. Individualized mite‐specific SLIT was administered orally for 12 months. All cats underwent clinical examination to record SCORing feline allergic dermatitis (SCORFAD), pruritus Visual Analog Scale (pVAS) and serum allergen‐specific IgE and IgG, every three months for 12 months.Results: Sixteen of 22 cats (73%) completed the study and three of six cats withdrawn from the study were included in an intention‐to‐treat analysis. SCORFAD and pVAS values decreased significantly from baseline (T0) to the third month of treatment (P = 0.0004 and P = 0.0013, respectively), with median total values ranging from 19 (6–44) (T0) to 2.5 (0–17) (T12) (P = 0.0001), and from 8 (6–10) (T0) to 2.3 (0–8) (T12) (P = 0.0001), respectively. Allergen‐specific IgE values decreased significantly from the ninth month (T9) of treatment (P = 0.0032), with median scores decreasing from 56 (12–729) (T0) to 34 (0–158) (T12) (P = 0.0208). No significant differences in allergen‐specific IgG values were observed throughout the study. No adverse effects related to the use of SLIT were reported.Conclusions and clinical importance: Sublingual immunotherapy should be considered a rapid, effective, safe and well‐tolerated treatment in cats with feline atopic dermatitis fAD.
- 5 January 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (1) , 67-e12
Clinical efficacy of sublingual allergen‐specific immunotherapy in 22 cats with atopic dermatitis
Background: Sublingual immunotherapy (SLIT) has been deployed in humans and dogs; to the best of the authors’ knowledge, there are no published studies about the use of SLIT in cats.Objectives: Evaluate the clinical efficacy of SLIT in atopic cats sensitized to dust and storage mites, assessing immunological changes associated with SLIT treatment.Animals: Twenty‐two client‐owned cats with clinical signs compatible with feline atopic dermatitis (fAD) and serum allergen‐specific immunoglobulin (Ig)E against house dust and storage mites.Methods and materials: Prospective, multicentre, open‐label clinical trial. Individualized mite‐specific SLIT was administered orally for 12 months. All cats underwent clinical examination to record SCORing feline allergic dermatitis (SCORFAD), pruritus Visual Analog Scale (pVAS) and serum allergen‐specific IgE and IgG, every three months for 12 months.Results: Sixteen of 22 cats (73%) completed the study and three of six cats withdrawn from the study were included in an intention‐to‐treat analysis. SCORFAD and pVAS values decreased significantly from baseline (T0) to the third month of treatment (P = 0.0004 and P = 0.0013, respectively), with median total values ranging from 19 (6–44) (T0) to 2.5 (0–17) (T12) (P = 0.0001), and from 8 (6–10) (T0) to 2.3 (0–8) (T12) (P = 0.0001), respectively. Allergen‐specific IgE values decreased significantly from the ninth month (T9) of treatment (P = 0.0032), with median scores decreasing from 56 (12–729) (T0) to 34 (0–158) (T12) (P = 0.0208). No significant differences in allergen‐specific IgG values were observed throughout the study. No adverse effects related to the use of SLIT were reported.Conclusions and clinical importance: Sublingual immunotherapy should be considered a rapid, effective, safe and well‐tolerated treatment in cats with feline atopic dermatitis fAD.
- 26 November 2019
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (2) , 134-137
A pharmacokinetic study of oclacitinib maleate in six cats
Background Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. Objective To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. Animals Six adult domestic short hair cats. Methods and materials A two period, two treatment design was used in which cats received oclacitinib maleate i.v. and p.o., at a dose of 0.5 mg/kg and 1 mg/kg, respectively. There was a one‐week interval of washout between the two treatments. Cats received each treatment only once. The plasma concentration of oclacitinib was determined by high‐performance liquid chromatography at 0 min, 5 min, 15 min, 30 min, 1 h, 4 h, 6 h, 10 h and 24 h after intravenous.v administration, at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 10 h and 24 h after p.o. administration. Results After p.o. administration, oclacitinib was absorbed rapidly and almost completely, as shown by an absolute bioavailability of 87% and a Tmax of 35 min. The elimination of the drug also was very rapid as shown by a half‐life of 2.3 h and a clearance calculated as 4.45 mL/min/kg (after i.v. administration). Conclusions and clinical importance The pharmacokinetic parameters of oclacitinib in the cat are similar to those described for the dog, although absorption and elimination are somewhat faster and variability between individuals is somewhat greater. Larger doses and/or shorter dosing intervals would be recommended in cats to achieve similar blood concentrations to those in dogs.
- 26 November 2019
- Published by Wiley in Veterinary Dermatology
- Vol. 31 (2) , 134-137
A pharmacokinetic study of oclacitinib maleate in six cats
Background Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. Objective To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. Animals Six adult domestic short hair cats. Methods and materials A two period, two treatment design was used in which cats received oclacitinib maleate i.v. and p.o., at a dose of 0.5 mg/kg and 1 mg/kg, respectively. There was a one‐week interval of washout between the two treatments. Cats received each treatment only once. The plasma concentration of oclacitinib was determined by high‐performance liquid chromatography at 0 min, 5 min, 15 min, 30 min, 1 h, 4 h, 6 h, 10 h and 24 h after intravenous.v administration, at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 10 h and 24 h after p.o. administration. Results After p.o. administration, oclacitinib was absorbed rapidly and almost completely, as shown by an absolute bioavailability of 87% and a Tmax of 35 min. The elimination of the drug also was very rapid as shown by a half‐life of 2.3 h and a clearance calculated as 4.45 mL/min/kg (after i.v. administration). Conclusions and clinical importance The pharmacokinetic parameters of oclacitinib in the cat are similar to those described for the dog, although absorption and elimination are somewhat faster and variability between individuals is somewhat greater. Larger doses and/or shorter dosing intervals would be recommended in cats to achieve similar blood concentrations to those in dogs.
- 22 May 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (4) , 323-+
Topical polyhydroxy acid treatment for autosomal recessive congenital ichthyosis in the golden retriever: a prospective pilot study
Background: Autosomal recessive congenital ichthyosis (ARCI) in golden retrievers is due to a PNPLA1 gene mutation, which plays a role in epidermal lipid organization and metabolism. Topical therapies are used to reduce scaling; however, there are few published efficacy studies.Objectives: To examine the efficacy of topical treatment based on gluconolactone, a polyhydroxy acid with known beneficial effects on stratum corneum structure.Animals: Sixteen golden retriever dogs with clinical signs of ARCI and PCR‐confirmed PNPLA1 gene mutation.Methods: This was a prospective, multicentre, noncontrolled study. Dogs were treated with a shampoo and lotion containing gluconolactone and other hydroxyl acids. Treatments were administered initially twice weekly for two weeks, then once weekly for two weeks and finally once monthly. Examinations were performed prior to and at 14 and 30 days of treatment to assess scaling, presence of other skin lesions and pruritus. In two dogs, pre‐ and 30 day post‐treatment, skin biopsies were obtained.Results: The extent and size of the scales were reduced by 60% and 75% after 14 and 30 days of treatment, respectively (P < 0.001). In 20% of the dogs, scaling was no longer observed after the first 30 days of treatment. No other skin lesions or pruritus were observed in any dog. Post‐treatment biopsies showed normalization of the stratum corneum morphology and reduced hyperpigmentation.Conclusion and clinical importance: The frequent use of a shampoo and lotion containing gluconolactone may be an effective measure to improve skin scaling in golden retrievers with ARCI.
- 22 May 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (4) , 323-+
Topical polyhydroxy acid treatment for autosomal recessive congenital ichthyosis in the golden retriever: a prospective pilot study
Background: Autosomal recessive congenital ichthyosis (ARCI) in golden retrievers is due to a PNPLA1 gene mutation, which plays a role in epidermal lipid organization and metabolism. Topical therapies are used to reduce scaling; however, there are few published efficacy studies.Objectives: To examine the efficacy of topical treatment based on gluconolactone, a polyhydroxy acid with known beneficial effects on stratum corneum structure.Animals: Sixteen golden retriever dogs with clinical signs of ARCI and PCR‐confirmed PNPLA1 gene mutation.Methods: This was a prospective, multicentre, noncontrolled study. Dogs were treated with a shampoo and lotion containing gluconolactone and other hydroxyl acids. Treatments were administered initially twice weekly for two weeks, then once weekly for two weeks and finally once monthly. Examinations were performed prior to and at 14 and 30 days of treatment to assess scaling, presence of other skin lesions and pruritus. In two dogs, pre‐ and 30 day post‐treatment, skin biopsies were obtained.Results: The extent and size of the scales were reduced by 60% and 75% after 14 and 30 days of treatment, respectively (P < 0.001). In 20% of the dogs, scaling was no longer observed after the first 30 days of treatment. No other skin lesions or pruritus were observed in any dog. Post‐treatment biopsies showed normalization of the stratum corneum morphology and reduced hyperpigmentation.Conclusion and clinical importance: The frequent use of a shampoo and lotion containing gluconolactone may be an effective measure to improve skin scaling in golden retrievers with ARCI.